Trexquant Investment LP Fate Therapeutics Inc Transaction History

Trexquant Investment LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$3.54 - $8.35 $912,314 - $2.15 Million	257,716 New	257,716 $1.89 Million
Q2 2023 Aug 11, 2023	SELL	$4.76 - $6.59 $149,464 - $206,926	-31,400 Reduced 8.59%	333,986 $1.59 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $735,423 - $1.93 Million	173,449 Added 90.37%	365,386 $2.08 Million
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $1.27 Million - $3.08 Million	129,049 Added 205.2%	191,937 $1.94 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $1.14 Million - $1.95 Million	54,168 Added 621.19%	62,888 $1.41 Million
Q2 2022 Aug 11, 2022	BUY	$17.78 - $42.39 $155,041 - $369,640	8,720 New	8,720 $216,000
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $738,075 - $992,637	-15,428 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $914,417 - $1.48 Million	15,428 New	15,428 $914,000
Q2 2021 Aug 12, 2021	SELL	$67.25 - $92.52 $908,951 - $1.25 Million	-13,516 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$72.16 - $117.4 $177,585 - $288,921	2,461 Added 22.26%	13,516 $1.11 Million
Q4 2020 Feb 11, 2021	BUY	$38.09 - $100.95 $421,084 - $1.12 Million	11,055 New	11,055 $1.01 Million
Q1 2020 May 08, 2020	SELL	$17.28 - $31.88 $576,685 - $1.06 Million	-33,373 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$13.39 - $20.73 $446,864 - $691,822	33,373 New	33,373 $653,000
Q2 2018 Aug 07, 2018	SELL	$9.16 - $13.48 $168,260 - $247,614	-18,369 Closed	0 $0
Q1 2018 May 03, 2018	BUY	$6.3 - $13.77 $115,724 - $252,941	18,369 New	18,369 $179,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.